Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436422 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT01436422 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 112 participants.
The verdict
NCT01436422, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TetraVax-DV Vaccine - Admixture TV003
- BIOLOGICAL TetraVax-DV Vaccine - Admixture TV005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436422
The ClinicalTrials.gov registry entry for NCT01436422 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01436422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01436422 about?
NCT01436422 is a clinical study titled "Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine". Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults.
What is the current status of trial NCT01436422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2011-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01436422?
The interventions under investigation include: Placebo (BIOLOGICAL), TetraVax-DV Vaccine - Admixture TV003 (BIOLOGICAL), TetraVax-DV Vaccine - Admixture TV005 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01436422?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.